

**PATENT AGENT**

Portland Office
503.473.0949
steven.burgess@klarquist.com

EDUCATION

Ph.D., Chemistry, Portland State University, 2008

B.Sc. (*Hons*) in Chemistry, University of Bristol, U.K., 1992

ADMISSIONS

U.S. Patent and Trademark Office, 2013 (Reg. No. 71,428)

PRACTICE AREAS

Patents

TECHNOLOGIES

Chemical
Electrical & Semiconductors
Nanotechnology

Steven J. Burgess, Ph.D.

Steven prepares and prosecutes U.S. patent applications and assists with the preparation and prosecution of international and foreign patent applications.

Steven is a patent agent skilled in all aspects of chemistry. He has more than 15 years of industrial experience in synthetic organic and medicinal chemistry including drug discovery, small molecule synthesis and drug product intermediates, as well as nanoparticles, thin films and coatings, and semiconductors. Prior to joining Klarquist, he worked at a drug discovery company, designing and synthesizing novel antimalarial and antibacterial drugs. He also previously worked at a chemical company designing libraries for high-throughput screening, and synthesizing heterocyclic building blocks and intermediates for drug discovery and pharmaceutical customers.

Steven joined Klarquist as a patent agent in 2013.

Professional Experience

- DesignMedix
Portland, Oregon
Senior Scientist, 2008 – 2013
Designed and synthesized novel antimalarial and antibacterial drugs. Project manager for the preclinical testing of the lead RCQ candidate.
- Portland State University
Portland, Oregon
Research/Teaching Assistant, 2003 – 2008
Dissertation title: Design and synthesis of antimalarial drugs based on a chloroquine scaffold.
- Maybridge Chemical Company
Tintagel, Cornwall, England
Scientist, 2001 – 2003
Team Leader, 1999 – 2001
Senior Chemist, 1995 – 1999
Chemist, 1992 – 1995
Designed and synthesized screening libraries, and synthetic intermediates, and managed custom synthesis projects.

Professional Activities

- Reviewer, Journal of Medicinal Chemistry

Klarquist

Honors & Awards

- Paul Emmett Outstanding Graduate Student Award, 2007

Presentations & Publications

- Gunsaru B, Burgess SJ, Morrill W, Kelly JX, Shomloo S, Smilkstein MJ, Liebman K, Peyton DH. 2017. Simplified reversed chloroquines to overcome malaria resistance to quinoline-based drugs. *Antimicrob Agents Chemother* 61:e01913-16
- Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Noviyanti R, Kenangalem E, Poespoprodjo JR, Burgess SJ, Peyton DH, Price RN, Marfurt J. 2015. Contrasting ex vivo efficacies of “reversed chloroquine” compounds in chloroquine-resistant *Plasmodium falciparum* and *P. vivax* isolates. *Antimicrob Agents Chemother* 59:5721–5726
- Burgess, SJ; Kelly, JX; Shomloo, S; Wittlin, S; Brun, R; Liebmann, K; Peyton, DH: Synthesis, Structure-Activity Relationship, and Mode-of-Action Studies of Antimalarial Reversed Chloroquine Compounds. *J. Med. Chem.* 2010, 53(17): 6477-6489
- Andrews S, Burgess SJ, Skaalrud D, Kelly JX, Peyton DH: Reversal agent and linker variants of reversed chloroquines: activities against *Plasmodium falciparum*. *J. Med. Chem.* 2010, 53(2):916-919
- Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH: A Chloroquine-like Molecule Designed to Reverse Resistance in *Plasmodium falciparum*. *J. Med. Chem.* 2006, 49(18):5623-56